UNCY

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

Unicycive Therapeutics faces second FDA CRL; securities investigation prompts caution

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>The FDA issued a second Complete Response Letter for UNCY&#039;s resubmitted OLC NDA, citing the same third-party manufacturing deficiencies as the prior CRL and noting that FDA inspection of the vendor had not yet occurred. Johnson Fistel initiated an investor investigation into potential misstatements or omissions. The combination of regulatory delay and legal scrutiny is likely to keep UNCY shares volatile in the near term.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel launches investor investigation into UNCY after FDA CRL.</li><li>FDA issued second Complete Response Letter for UNCY&#039;s OLC NDA.</li><li>CRL cites same third-party manufacturing deficiencies; vendor inspection not yet completed.</li><li>UNCY stock declined following news; legal probe adds regulatory risk.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Unicycive Therapeutics, Inc. (UNCY)</strong>: Regulatory delay and ongoing NDA review create near-term price sensitivity.</li><li><strong>Johnson Fistel, PLLP</strong>: Legal/consumer-investor investigator; potential to amplify negative sentiment and information flow.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Legal; the piece centers on a securities investigation announced by a law firm amid a regulatory setback for UNCY, highlighting potential financial and disclosure risks that could influence valuation and investor behavior.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>UNCY shares declined after CRL and investigation news.</li><li>CRL references prior third-party manufacturing deficiencies, delaying NDA timeline.</li><li>FDA hasn&#039;t inspected the third-party vendor, increasing execution risk.</li><li>Legal inquiry may heighten stock discount to valuation and funding needs.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Date: June 30, 2026.</li><li>FDA issued a second Complete Response Letter for UNCY&#039;s resubmitted OLC NDA.</li><li>CRL based on the same third-party manufacturing deficiencies identified in June 2025.</li><li>FDA had not yet conducted its vendor inspection as part of the resubmission review.</li><li>UNCY stock price declined following the news.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bearish near-term risk until FDA timeline clarity and any legal disclosures emerge (1–3 quarters).</p>
  </section>
</section>


<article>
  <h2>Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors</h2>

  <p>SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating <strong>Unicycive Therapeutics, Inc.</strong> (<strong>NASDAQ: UNCY</strong>) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.</p>

  <p>If you purchased Unicycive securities and suffered losses on your investment, you are encouraged to contact Johnson Fistel to learn more about the investigation.</p>

  <p><a href="https://www.globenewswire.com/Tracker?data=_q1W5HwHW0hDNNFFGFqIS-oNdnzY2MXWMf2Uyhd0SCrDZ7WWvbOt78x7-h-IDjEEnH_wOdLLYsrBTYFhL6h0bgGNjTXGm6unlJYNa1cu459CBXKdBO4TZ27GYGZlra-cV_klkC6yJP_JhPfovZ8KbgfFvX4r6vP8pWpTJ_xwMQWq9x84mrK41xIgv2v5XB-t" rel="nofollow" target="_blank">Click Here to Join the Investigation</a></p>

  <section>
    <h3>Key Facts and Timeline</h3>
    <ul>
      <li>Company: <strong>Unicycive Therapeutics, Inc.</strong> (<strong>NASDAQ: UNCY</strong>)</li>
      <li>Event type: General News – securities investigation on behalf of investors</li>
      <li>Date announced: <strong>June 30, 2026</strong></li>
      <li>Regulatory update: On <strong>June 30, 2026</strong>, Unicycive announced that the FDA had issued a second Complete Response Letter regarding the resubmitted OLC NDA</li>
      <li>CRL basis: based on the same third-party manufacturing deficiencies identified in the prior June 2025 CRL</li>
      <li>NDA status: FDA had not yet conducted its inspection of the third-party manufacturing vendor as part of the review process for the resubmitted NDA</li>
      <li>Market reaction: Following this news, Unicycive’s stock price declined</li>
      <li>Investor contact: jimb@johnsonfistel.com; (619) 814-4471</li>
    </ul>
  </section>

  <section>
    <h3>FDA CRL Update and NDA Status</h3>
    <p>On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter regarding the resubmitted OLC NDA. The Company disclosed that the CRL was based on the same third-party manufacturing deficiencies identified in the prior June 2025 CRL. Unicycive also stated that it understands the FDA had not yet conducted its inspection of the third-party manufacturing vendor as part of the review process for the resubmitted NDA.</p>

    <p>Following this news, Unicycive’s stock price declined.</p>
  </section>

  <section>
    <h3>Investigation Focus and Investor Guidance</h3>
    <p>In light of these disclosures, Johnson Fistel is investigating whether Unicycive made false or misleading statements or failed to disclose material information. If you suffered losses, or are a long-term holder of Unicycive stock, contact Johnson Fistel.</p>

    <p>Attorney advertising. Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. This press release may be considered a promotional communication. The attorney responsible for this communication is Frank J. Johnson.</p>
  </section>

  <section>
    <h3>Contact and Disclosure</h3>
    <p><strong>Contact</strong><br>Johnson Fistel, PLLP<br>501 W. Broadway, Suite 800<br>San Diego, CA 92101<br>James Baker, Investor Relations<br>(619) 814-4471<br><a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a></p>
  </section>

  <p>There is no cost or obligation to you.</p>

  <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc1NDk1MSM3Njg1MTExIzIxODE3ODk=">

  <img alt="" src="https://ml.globenewswire.com/media/MGRiNWZlYjUtNDQ1YS00NDBhLTg0MjAtMTliZjYxNzcxYzY2LTExOTMzNTgtMjAyNi0wNi0zMC1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade">

  <p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></a></p>
</article>

The FDA issued a second Complete Response Letter for UNCY's resubmitted OLC NDA, citing the same third-party manufacturing deficiencies as the prior CRL and noting that FDA inspection of the vendor had not yet occurred. Johnson Fistel initiated an investor investigation into potential misstatements or omissions. The combination of regulatory delay and legal scrutiny is likely to keep UNCY shares volatile in the near term.

Johnson Fistel Investigates Unicycive Therapeutics, Inc. (NASDAQ: UNCY) on Behalf of Investors

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News